Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Defining the Biochemical Function and Therapeutic Utility of Unique PARP14 and PARP15 ADP-Ribosylation Sites

Award Number: R15GM139150
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2028

Group Awards By:

View Award Description

Defining the Biochemical Function and Therapeutic Utility of Unique PARP14 and PARP15 ADP-Ribosylation Sites - SUMMARY ADP-ribosylation was one of the first post-translational modifications (PTMs) discovered. It is a widespread and ubiquitous post-translational modification across all kingdoms of life – whose biochemical selectivity, cellular consequences, and final fates remain poorly understood. Our objective is to investigate the entire life-cycle of the ADP-ribose modification; from ADP-ribose transfer, to the post-transfer alterations of that ADP-ribose, and the final removal of the resulting PTMs. We will use our findings to investigate the functions of the ADP-ribose signal transduction network and develop first-in-class peptide-based inhibitors to target malfunctioning ADP- ribose signaling networks. In humans, 17 different poly-ADP-ribose polymerases (PARPs) catalyze ADP- ribosylation, a separate set of enzymes convert ADP-ribose to phosphoribose, and 6 glycohydrolases remove ADP-ribose. Importantly, there are a multitude of glycohydrolases found in various viral species. The enzymes associated with ADP-ribose processing have been implicated in a variety of physiological functions (e.g., DNA repair, RNA regulation, cell development) and a broad array of diseases, most notably viral infection. While previous efforts have validated the roles for PARPs 14 and 15 in viral regulation, their mechanism of action remains unclear. In large part, this lack of clarity arises from our inability to connect a single site of ADP- ribosylation to its downstream function. Work in the kinase field has demonstrated the power of connecting enzyme-specific PTMs to their precise cellular function, fundamentally altering our understanding of signal transduction and revealing new avenues for therapeutic intervention in disease. By leveraging the expertise from my lab and that of my collaborators, our work will use a multidisciplinary approach to determine the functional consequences of unique ADP-ribosylation events in the cell and develop novel viral glycohydrolase-selective peptide-based inhibitors to block specific ADP-ribose removals. In the first aim, we will identify the auto-modification sites on PARP14 and PARP15, linking specific ADP-ribosylation sites to cellular effects. We have extensive experience working with these PARPs and we have a robust viral model to interrogate how specific site alterations change pathway behavior. In the second aim, a PARP14-specific target peptide sequence that we have developed will serve as a platform to identify selective viral glycohydrolase inhibitors. We will synthesize peptide and peptoid (poly-N-substituted glycine) derivatives of the initial target peptide and identify structure activity relationships (SAR analysis) with the resulting library to optimize promising antivirals. In the third aim, we will map the biochemical pathway responsible for converting ADP-ribose to phosphoribose. We will identify the phosphoribose interactome and investige its role in the innate antiviral response. This research will enhance our mechanistic understanding of ADP-ribosylation and offer new strategies for targeting viral glycohydrolase enzymes, with broader implications for studying PARPs, glycohydrolases, and ADP-ribose processing in medicine and cell biology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $507,796 )
2025	2025	PRESIDENT AND BOARD OF TRUSTEES OF SANTA CLARA COLLEGE	500 EL CAMINO REAL	SANTA CLARA	CA	95050	SANTA CLARA	USA	Biomedical Research and Research Training	001	2	9/5/2025	COMPETING CONTINUATION	$507,796
2025	2020	PRESIDENT AND BOARD OF TRUSTEES OF SANTA CLARA COLLEGE	500 EL CAMINO REAL	SANTA CLARA	CA	95050	SANTA CLARA	USA	Biomedical Research and Research Training	000	1	1/29/2025	NEW	$0
														Subtotal = $507,796

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2020	PRESIDENT AND BOARD OF TRUSTEES OF SANTA CLARA COLLEGE	500 EL CAMINO REAL	SANTA CLARA	CA	95050	SANTA CLARA	USA	Biomedical Research and Research Training	000	1	5/31/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $388,494 )
2020	2020	PRESIDENT AND BOARD OF TRUSTEES OF SANTA CLARA COLLEGE	500 EL CAMINO REAL	SANTA CLARA	CA	95050	SANTA CLARA	USA	Biomedical Research and Research Training	000	1	7/16/2020	NEW	$388,494
														Subtotal = $388,494

Grand Total All Awards = $896,290

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Defining the Biochemical Function and Therapeutic Utility of Unique PARP14 and PARP15 ADP-Ribosylation Sites

Award Number: R15GM139150

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer